Prague, Czech Republic
Prague, Czech Republic

Time filter

Source Type

Conservancy scientists estimate that less than 10 percent of soils in the United States are managed optimally today. Furthermore, the increasing demand for food, fuel and fiber production by a growing global population is placing unprecedented stress on the health and viability of soil. The Food and Agriculture Organization of the United Nations estimates a 60 percent increase in global food production is required by 2050 to meet the rising demand. "We understand and appreciate that healthy soil is the foundation for healthy agricultural products that nourish people and pets. Soil underlies all of our quality ingredients grown and raised in the U.S., including soy, corn, wheat, rice and meat," said Jack Scott, Head of Sustainability at Nestlé Purina PetCare Company. "We are proud to be a partner in the reThink Soil effort with The Nature Conservancy and its many collaborators." The reThink Soil initiative spans the science, business and policy sectors to advance the widespread adoption of soil health practices — including cover crops, conservation tillage and crop rotation —  on at least 50 percent of U.S. croplands by 2025. To accomplish this, the Conservancy is working with the Soil Health Partnership, the largest data-driven, farmer-led soil health research project of its kind, and the Soil Health Institute, a leader in scientific research and advancement of soil health. Together they are working to enact a 10-point strategic roadmap to achieve meaningful soil health outcomes at an unprecedented rate and scale. Strategies include working to improve soil health measurements and standards, increasing support for soil health practice adoption by absentee landowners, expanding the network of on-farm demonstration sites and advancing public policy solutions. Nestlé Purina is the first pet care company to support this initiative, and this commitment will also enable other parts of Nestlé's food business to engage in the work. "With this commitment to our soil health work, Nestlé Purina PetCare Company is continuing its generous support of conservation efforts to help ensure healthy lands and waters while empowering farmers to grow bountiful crops in a sustainable way," Clemens said. Last year, Nestlé Purina PetCare Company's support enabled the Conservancy to build upon decades of work along the Wabash River in Indiana, a critical tributary of the Mississippi River Basin, to reduce nutrient and sediment flow by installing wetlands and woodlands at key junctures (watch a video about the work at Nature.org/Wabash). The company is further supporting the Conservancy's work by investing in reThink Soil to help provide farmers throughout the U.S. with the information, resources and tools needed to advance soil health, and in turn, secure their livelihoods and protect natural resources. "Nestlé Purina and our parent company, Nestlé, are committed to balanced ecosystems that provide cleaner water with less runoff and erosion, as well as increased carbon sequestration and biodiversity," said Diane Herndon, Senior Manager of Sustainability at Nestlé Purina PetCare Company. "We applaud all of the progress that America's farmers have achieved over the years to grow abundant and nutritious crops, and we look forward to working with them and many other partners to continue this progress." Nestlé Purina PetCare promotes responsible pet care, community involvement and the positive bond between people and their pets. A premiere global manufacturer of pet products, Nestlé Purina PetCare is part of Swiss-based Nestlé S.A., a global leader in nutrition, health and wellness. The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at unprecedented scale, and helping make cities more sustainable. Working in more than 65 countries, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org/soil or follow @nature_press on Twitter. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nestle-purina-petcare-company-supports-the-nature-conservancys-national-soil-health-initiative-with-1-million-commitment-300461516.html


News Article | May 24, 2017
Site: www.businesswire.com

DETROIT--(BUSINESS WIRE)--Iconic American denim brand Wrangler® today announced the launch of a pilot program to help U.S. cotton farmers reach the next level in sustainable growing practices. The announcement took place at the Sustainable Brands conference in Detroit, where Wrangler co-hosted the Good Apparel pavilion. Wrangler purchases roughly half of the cotton for its products from U.S. growers. The U.S. cotton industry outperforms most other cotton-growing regions of the world on environmental metrics. However, Wrangler wants to determine how even greater environmental and economic benefits can be achieved through a programmatic focus on soil health in the U.S. “Scientific research shows greater attention to soil health can further reduce the water and energy inputs required to grow cotton and other crops,” explained Wrangler sustainability director, Roian Atwood. “We’re working with a cotton grower in Alabama to explore the best way to implement and measure the effects of robust soil practices like no-till, crop rotation and cover cropping. We hope to have dozens of growers in the program within a few years.” The Newby family—seventh-generation farmers from Athens, Alabama—will work with Wrangler and advisors from the Soil Health Institute (SHI) to unlock further improvements in cotton yield, irrigation water, energy inputs, greenhouse gas emissions and soil conservation. Forty thousand pounds of the Newby’s cotton will be used to make a special collection of Wrangler denim jeans that will be sold in 2018. “Our family has always looked for new ways to make farming more economical, while taking better care of the land,” said Jerry Allen Newby. “There’s been a learning curve, but we’re beginning to see good results with things like cover crops and soil grid mapping. We’re happy to work with Wrangler, share what we’ve learned, and maybe make it easier for other growers to transition to these practices.” The pilot program builds on Wrangler’s long-standing commitment to supporting U.S. farming communities. Wrangler has been a corporate sponsor of Future Farmers of America for more than 50 years, and recently hosted a conference at Wrangler headquarters in Greensboro, North Carolina, to educate FFA youth on the science of soil health. A short video overview of that event is available here. Wrangler’s sustainability work is focused on three areas: land, people and industry. In addition to the cotton pilot project and soil health education, other programs include a commitment to 100% renewable electricity by 2025, zero waste facilities, and manufacturing and technology improvements that have saved 3 billion liters of water over the last decade. Learn more on Wrangler’s sustainability website. About Wrangler® Wrangler® apparel is available nationwide in mass market retailers, specialty stores, including work apparel chains, farm & fleet, and western stores, as well as through online and catalog retailers. To find a retailer or for more information on the Wrangler family of products, visit Wrangler.com or call 888.784.8571.


Receive press releases from MedAware Systems, Inc.: By Email Broomfield, CO, May 03, 2017 --( Dr. Piland is a recognized authority in healthcare economics and research, Dr. Piland is Research Professor, Emeritus, Institute of Rural Health, Idaho State University. He also served as Director of the Institute for thirteen years. Dr. Piland brings over forty-five years of experience in health services research, health care financing, and healthcare economics. Prior to his tenure at Idaho State University, he served as Director of the Medical Group Management Center for Research; was founding director of the Lovelace Medical Foundation’s Institute for Health and Population Research. He also served as Health Economist and Assistant Manager of Health Services Research at Stanford Research Institute (now SRI International). Dr. Piland held senior administrative and faculty positions at the Colorado Health Institute; the University of Colorado School of Medicine; the University of New Mexico School of Medicine; the University of Denver; the San Diego Veterans Administration Medical Center; and the Veterans Medical Research Foundation. He served as Principal Investigator on more than 30 major health services research projects and published over 100 scientific and health policy related articles and book chapters and has coauthored four books. He holds numerous awards, including the Indian Health Service (USDHHS) Director Award; Professional Leadership Award from the American Lung Association; Scientific Research Award from the Lovelace Medical Foundation; and a United States Public Health Service Training Fellowship, among others. “We are honored to have Dr. Piland join our Scientific Advisory Board” said Founder and Chief Science Officer, Dr. Zung Vu Tran. He adds, “Dr. Piland brings a wealth of knowledge and experience in healthcare economics and research that will add critical economic data components that are highly valuable to our customers.” About MedAware Systems, Inc. MedAware Systems, Inc. disrupts the health informatics industry by forever changing the way Pharma and medical device companies, physicians, payers and consumers derive usable evidence from published clinical trials research. The Company’s Science of Health Informatics (SOHInfo™) is a Scientific-Data-as-a-Service (SDaaS™) solving the problem of making the vast and chaotic body of human clinical trials research instantly available and indispensable in understanding medical treatment safety and efficacy. SOHInfo organizes and standardizes data from all human clinical trials and provides immediate and actionable information on evidence-based medical treatments and outcomes. Broomfield, CO, May 03, 2017 --( PR.com )-- MedAware Systems, Inc. announced today that Dr. Neill Piland is joining the Company’s Scientific Advisory Board.Dr. Piland is a recognized authority in healthcare economics and research, Dr. Piland is Research Professor, Emeritus, Institute of Rural Health, Idaho State University. He also served as Director of the Institute for thirteen years.Dr. Piland brings over forty-five years of experience in health services research, health care financing, and healthcare economics. Prior to his tenure at Idaho State University, he served as Director of the Medical Group Management Center for Research; was founding director of the Lovelace Medical Foundation’s Institute for Health and Population Research. He also served as Health Economist and Assistant Manager of Health Services Research at Stanford Research Institute (now SRI International). Dr. Piland held senior administrative and faculty positions at the Colorado Health Institute; the University of Colorado School of Medicine; the University of New Mexico School of Medicine; the University of Denver; the San Diego Veterans Administration Medical Center; and the Veterans Medical Research Foundation.He served as Principal Investigator on more than 30 major health services research projects and published over 100 scientific and health policy related articles and book chapters and has coauthored four books. He holds numerous awards, including the Indian Health Service (USDHHS) Director Award; Professional Leadership Award from the American Lung Association; Scientific Research Award from the Lovelace Medical Foundation; and a United States Public Health Service Training Fellowship, among others.“We are honored to have Dr. Piland join our Scientific Advisory Board” said Founder and Chief Science Officer, Dr. Zung Vu Tran. He adds, “Dr. Piland brings a wealth of knowledge and experience in healthcare economics and research that will add critical economic data components that are highly valuable to our customers.”About MedAware Systems, Inc.MedAware Systems, Inc. disrupts the health informatics industry by forever changing the way Pharma and medical device companies, physicians, payers and consumers derive usable evidence from published clinical trials research. The Company’s Science of Health Informatics (SOHInfo™) is a Scientific-Data-as-a-Service (SDaaS™) solving the problem of making the vast and chaotic body of human clinical trials research instantly available and indispensable in understanding medical treatment safety and efficacy. SOHInfo organizes and standardizes data from all human clinical trials and provides immediate and actionable information on evidence-based medical treatments and outcomes. Click here to view the list of recent Press Releases from MedAware Systems, Inc.


Global Medical Aesthetics Market Forecast to 2024 – New Report by Data Bridge Market Research Global Medical Aesthetic Market, By Product Type (Aesthetic Laser Devices, Energy Devices, Skin Tightening and Body Contouring Devices, Aesthetic Implants, Facial Aesthetic Devices), By Applications (Anti Aging and Wrinkles, Facial & Skin Rejuvenation, Vascular Lesions, Body shaping & cellulite, Breast Enhancement, Scars, Pigment Lesions, Reconstructive Surgery, Tattoo Removal, Psoriasis & Vitilgo, Skin Surgery), End-User, Distribution Channel, Geography – Industry Trends and Forecast to 2024 Dallas, TX, February 18, 2017 --( The global medical aesthetic devices market is segmented on the basis of product type, application, end-user, distribution channel and geography. On the basis of product type the market is segmented into Aesthetic Laser devices which is further sub divided into Fractional Carbon Dioxide Laser Resurfacing, Ablative Skin Resurfacing Devices, Non-Ablative Fractional Laser Skin Resurfacing; Energy Devices which is further segmented into Electrocautery, Electrosurgery, Cryosurgery, Laser surgery, Microwave, Harmonic scalpel. Based on application the market is segmented into food and beverage testing, pharmaceutical, industrial, environmental testing, geological sciences, petrochemical, academics and, others. On the basis of application the market is segmented into anti aging and wrinkles, facial & skin rejuvenation, vascular lesions, body shaping & cellulite, breast enhancement, scars, pigment lesions, reconstructive surgery, tattoo removal, hair removal, psoriasis & vitilgo, skin tightening and others. Based on end user the market is segmented into hospitals, dermatology clinics, cosmetic centers, medical spas & beauty center. Request for sample pages: https://databridgemarketresearch.com/reports/global-medical-aesthetics-market/ Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report of this market covers data for countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa. Read more: https://databridgemarketresearch.com/medical-aesthetics-market-poised-grow-8-6/ The key players operating in this market are Allergan plc, Neograft Technologies Inc, BTL Aesthetics, Galderma S.A., Thermi, Merz Pharma Gmbh & Co, Surgical Specialties Corporation, Suneva Medical, Venus concept, Valeant Pharmaceuticals International, Sientra Inc, Cynosure Inc, Revance Therapeutics Inc, Zeltiq Aesthetics Inc, Dynatronics Corporation, EternoGen Aesthetics, GC Aesthetics, Obagi Skin Health Institute, Dermatology Associates, Alma Lasers GmbH, Cutera Inc, Cynosure Inc, Ellman International Inc, Genesis Biosystems Inc, Iridex Corporation, PhotoMedex Inc, Sciton Inc, Smith & Nephew Healthcare Pvt. Ltd., Solta Medical Corporate, Syneron Medical Ltd, Laboratories Vivacy, Prollenium Medical Technologies among others. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Dallas, TX, February 18, 2017 --( PR.com )-- The Global medical aesthetics market is expected to reach USD 16.1 billion by 2024 from USD 8.33 billion in 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.The global medical aesthetic devices market is segmented on the basis of product type, application, end-user, distribution channel and geography.On the basis of product type the market is segmented into Aesthetic Laser devices which is further sub divided into Fractional Carbon Dioxide Laser Resurfacing, Ablative Skin Resurfacing Devices, Non-Ablative Fractional Laser Skin Resurfacing; Energy Devices which is further segmented into Electrocautery, Electrosurgery, Cryosurgery, Laser surgery, Microwave, Harmonic scalpel. Based on application the market is segmented into food and beverage testing, pharmaceutical, industrial, environmental testing, geological sciences, petrochemical, academics and, others.On the basis of application the market is segmented into anti aging and wrinkles, facial & skin rejuvenation, vascular lesions, body shaping & cellulite, breast enhancement, scars, pigment lesions, reconstructive surgery, tattoo removal, hair removal, psoriasis & vitilgo, skin tightening and others.Based on end user the market is segmented into hospitals, dermatology clinics, cosmetic centers, medical spas & beauty center.Request for sample pages: https://databridgemarketresearch.com/reports/global-medical-aesthetics-market/Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report of this market covers data for countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.Read more: https://databridgemarketresearch.com/medical-aesthetics-market-poised-grow-8-6/The key players operating in this market are Allergan plc, Neograft Technologies Inc, BTL Aesthetics, Galderma S.A., Thermi, Merz Pharma Gmbh & Co, Surgical Specialties Corporation, Suneva Medical, Venus concept, Valeant Pharmaceuticals International, Sientra Inc, Cynosure Inc, Revance Therapeutics Inc, Zeltiq Aesthetics Inc, Dynatronics Corporation, EternoGen Aesthetics, GC Aesthetics, Obagi Skin Health Institute, Dermatology Associates, Alma Lasers GmbH, Cutera Inc, Cynosure Inc, Ellman International Inc, Genesis Biosystems Inc, Iridex Corporation, PhotoMedex Inc, Sciton Inc, Smith & Nephew Healthcare Pvt. Ltd., Solta Medical Corporate, Syneron Medical Ltd, Laboratories Vivacy, Prollenium Medical Technologies among others.About Data Bridge Market Research:Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Click here to view the list of recent Press Releases from Data Bridge Market Research


News Article | March 3, 2017
Site: www.PR.com

Cyrex Laboratories Adds Unique Expertise with Two New Team Members Cyrex Laboratories continues to attract the best and brightest in immunology testing with additions of Dr. Mark Engelman and Michelle Clark. Phoenix, AZ, March 03, 2017 --( Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine. Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico. “The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.” Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System. Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition. “Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark. Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information. About Cyrex Laboratories Cyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Phoenix, AZ, March 03, 2017 --( PR.com )-- Cyrex Laboratories, a leading clinical laboratory specializing in functional immunology and autoimmunity, continues to attract the highest caliber professionals to the organization. With the addition of Dr. Mark Engelman, M.D., FSCM, ABAARM, FAARM, and Michelle Clark, MBA, Cyrex further reinforces its team’s expertise in functional medicine and laboratory business development.Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine.Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico.“The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.”Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System.Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition.“Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark.Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information.About Cyrex LaboratoriesCyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Click here to view the list of recent Press Releases from Cyrex Laboratories


The medical tourism industry in Malaysia is booming, which contributed to the fierce competition among the leading market players. Because the market is heading towards its maturity, a majority of the prominent enterprises are looking to offer dynamic changes in their services and products to keep reporting sustainable growth. Despite the presence of a large number of companies, the Medical Tourism Market in Malaysia still exhibits a high degree of consolidation, with the leading players holding the crux of the market, finds Transparency Market Research (TMR) in a new report. Some of the leading companies exhibiting a strong presence in the Malaysia medical tourism market are KPJ Healthcare Berhad, Prince Court Medical Centre, IJN Health Institute, Sunway Medical Centre, and Island Hospital. These institutions are focusing on emerging dominant by expanding their geographic footprint. Enhancing their foreign customer base has therefore become a key tactic for enterprises looking to establish a stronghold in the Malaysia medical tourism market. According to TMR, the medical tourism market in Malaysia is forecast to expand a whopping 30.05% CAGR between 2016 and 2024. At this incredible pace, the market will reach US$3.5 bn by the end of 2024, from a valuation of US$424.96 mn in 2016. Approximately 36.6% of medical tourists availed dental treatments in 2016, making it a leading market segment. Besides this, the market also witnessed considerably high demand in aesthetics/cosmetic surgery procedures and health screening segments. Low cost of medical services, compared to the same offered in developed economies of North America and Europe is the chief factor luring foreign medical tourists to Malaysia. Besides this, persistent government activities to boost the sector will synergize the country's medical tourism industry. "With the rising influx of medical tourists from MENA and neighboring countries, the medical tourism market in Malaysia is poised to surge exponentially in the coming years," said a lead TMR analyst. The accelerated pace of gains witnessed in the medical tourism market in Malaysia is contributed by excellent macro-economic factors such as the increasing government programs promoting medical tourism, excellent transport facilities, and decent recuperation facilities. For instance, to boost medical tourism, the Malaysian government offers varied tax incentives, especially on the revenue generated from foreign patients. "In 2009, the government offered tax exemption of 50% on revenues earned from foreign patients, which was later increased to a whopping 100% by the end of 2010," said a lead TMR analyst. Moreover, medical tourism is considered as one of the 12 national key economic areas (NKEAs) in Malaysia, which is a chief driver of the market. On the downside, medical inflation recorded in 2015 and a slight drop in the number of medical travelers could have an adverse influence on the market. Besides this, the market is already witnessing challenges from low revenue generated per patient, soaring healthcare costs, and the mounting burden on Malaysia's healthcare system. Nevertheless, Malaysia is positioned as a preferred destination for medical travelers, which has potentiated the country's medical tourism market. This review is based on a TMR PR, titled "Medical Tourism Market - Malaysia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." The report segments the Malaysia medical tourism market as: Regenerative Medicine Market (Bone and Joint) (Technology - Stem Cell Therapy, Biomaterial and Tissue Engineering; Application - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 Ophthalmology Diagnostics and Surgical Devices Market (Optical Coherence Tomography, Echography, Corneal Topographers, Specular Microscopes, Cataract, Refractive, Glaucoma and Vitreoretinal Surgery Devices) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


News Article | December 13, 2016
Site: www.businesswire.com

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced that Alexis V. Lukianov has been named to its Board of Directors. Mr. Lukianov’s appointment expands the Board to 10 directors, 9 of whom are independent directors. With more than 30 years’ experience, and an extensive background in orthopedics, Mr. Lukianov has held senior executive positions with companies such as Medtronic SofamorDanek and Smith and Nephew Orthopaedics, where he was the director of a business unit that brought limb lengthening technology to the United States from Russia. He was the founder of and served as the Chairman of the Board and CEO of BackCare Group, Inc., a spine physician practice management company, and from 1999-2015, Mr. Lukianov served as the Chairman and CEO at NuVasive, Inc. “We are pleased that Alex Lukianov will join our Board of Directors. As a senior experienced executive in the med-tech industry, Alex will be a valued strategic participant as we continue to focus on developing our growth opportunities,” said Ron Matricaria, Chairman of the Board. An entrepreneur, Mr. Lukianov has served on a variety of public, private and not-for-profit boards including the Volcano Corporation, the California Health Institute, BIOCOM, and the Medical Device Manufacturers Association (MDMA). Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, TX, the company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the company’s sales representatives, distributors and subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as Brown University, Sinai Hospital of Baltimore, Cleveland Clinic, Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation. For more information, please visit www.orthofix.com.


News Article | December 23, 2016
Site: www.prnewswire.co.uk

Real World Evidence of PU Reduction Using Early-Detection Technology - An Attack on the UK's £2.1bn Health Problem MANCHESTER, England and LOS ANGELES, Dec. 23, 2016 /PRNewswire/ -- Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%. Nurses dramatically cut bedsore occurrence by detecting damage developing under patients' skin early enough to intervene and reverse the damage. This marks a breakthrough in prevention of the chronic condition costing the UK £2.1bn annually, which claimed the life of Superman actor Christopher Reeve. Bruin Biometrics ("BBI LLC"), which manufactures the early detection technology known as the SEM Scanner, enlisted 13 hospitals (including 10 NHS England Trusts) to participate in a novel Pressure Ulcer Prevention Program (PURP) incorporating SEM Scanner into existing care pathways for pressure ulcer prevention. The findings from over 1200 patients scanned are the most comprehensive real-world evidence that this early detection technology enables nurses to prevent bedsores before they break through the skin, a conclusion that upends the prevailing view that bedsores cannot be diagnosed and treated until they have caused visible and irreversible damage to the skin's surface. "These data challenge existing practice that looks for visual changes to skin to initiate bedsore intervention," BBI CEO Martin Burns said. "Scientific findings show that by the time damage is visible, it is far too late. Early detection changed the prognosis for millions of cancer survivors. A proactive approach to 'Act Before Red' is consistently doing the same for bedsores, on a large scale, across independent sites." "We reduced pressure ulcers in the ward concerned to zero during our Scanner trial – an achievement that, if we rolled out across our hospital, we estimate could save our hospital nearly £600,000 and release 1,420 hours of nurse productivity annually," said Glenn Smith, a tissue viability and nutrition senior clinical nurse specialist/patient safety lead at St. Mary's Hospital, part of the NHS Trust on the Isle of Wight, which has a large elderly population at risk for bedsores due to immobility. "In our pilot program, which included over 200 patients, we reduced bedsore incidence by 90%," said Rose Raizman, nurse practitioner, enterostomal therapist and pressure ulcer prevention at Scarborough and Rouge Hospital in Ontario, Canada. "SEM Scanner allows the clinician to 'visualise pathology' below the skin level before it becomes apparent at the surface, and should be used as the standard of care for pressure ulcer prevention." "The vast majority of nurses participating in our Scanner program said the device provided valuable clinical information," added Parker Moss, chief technology and transformation officer at Virgin Care, which experienced a 95 percent drop in the bedsore rate during an evaluation of the device at Farnham Community Hospital in Surrey, where it provides services to the NHS. SEM Scanner is a wireless non-invasive handheld device that assesses sub-epidermal moisture, or SEM, an indicator of early-stage damage beneath the skin surface as much as 10 days earlier than visual inspection by nurses. SEM Scanner was conceived by Barbara Bates-Jensen, a wound care expert and professor at the University of California at Los Angeles (UCLA), and adapted from seismology technology used on NASA's Mars landing craft to interrogate beneath the planet's surface.  Professor Bates-Jensen, Dr. Majid Sarrafzadeh, and Dr. William J. Kaiser, co-director of the UCLA Wireless Health Institute and a former engineer at Jet Propulsion Laboratories, partnered with BBI to adapt the space technology into the SEM Scanner. Bedsores, also known as pressure ulcers, are chronic wounds to the skin and tissue that often develop in patients who are immobile. Bedsores commonly lead to infection and death. In fact, bedsores kill more people annually than any form of cancer except lung cancer. There are nearly 500,000 bedsore cases annually in the UK. Until now, diagnosis has relied on visual inspection by nurses, which is subjective and which can only identify bedsores once visible damage to the skin has already begun. With early-detection, experts believe that over 80% of early-stage pressure ulcers can be prevented. "We've borrowed NASA's concept of 'Seeing the Unseen' to develop the first clinically-proven method for detecting unseen bedsores and alerting healthcare practitioners in real time when they begin to form under the skin," said Rachael Lester, BBI VP of Product. "With early detection, clinicians can initiate treatment before chronic damage develops. More and more clinicians are using the SEM Scanner and finding that they can overcome avoidable PUs, proving that ZERO is no longer Mission: Impossible." Real-world evaluation data presented by St. Mary's Hospital (Improved Patient Safety with Use of the SEM Scanner) and Virgin Care (Chasing Zero. Results from a New Pressure Ulcer Prevention Bundle) at the Wounds UK annual conference November 14-16 in Harrogate and are now being released publicly for the first time. About Bedsores Bedsores, also known as pressure ulcers, are a common medical problem that can lead to pain, disfigurement, infection and death. Pressure ulcers are an area of localized damage to the skin and underlying tissue – usually around an area of bony prominence, such as the sacrum, coccyx, heels, and hips – that results from pressure involving shear and/or friction. Across Europe and the United States, it is estimated that 18%-25% of patients in both acute care and long-term care settings suffer from pressure ulcers, disproportionately impacting the elderly and patients with limited mobility. There are some 2.5 million pressure ulcer cases annually in the European Union, and nearly 500,000 in the United Kingdom, which spends £2.1bn, or 4% of the NHS budget, on the condition. In the U.S., some 2.5 million Americans develop pressure ulcers annually in acute care facilities, and 60,000 Americans die annually from pressure ulcer complications such as cancer, sepsis, cellulitis, and MRSA. About BBI  Bruin Biometrics LLC, a pioneer in biometric-sensor based medical devices, is committed to the development of point-of-care diagnostic solutions for early detection and monitoring of chronic, preventable conditions. The company's first product is the SEM Scanner, a hand-held non-invasive device that assesses sub-epidermal moisture, a biomarker which has been found to detect early-stage pressure ulcers as much as 10 days earlier than visual observation. Pressure ulcers affect approximately 25% of acute care hospital and long-term care patients – typically the elderly and immobile. SEM Scanner is CE Mark approved and is currently in full commercial launch in the EU and Canada. SEM Scanner is not currently for sale in the United States. BBI is also developing OrthoSonos, a non-invasive device for real-time orthopaedic joint monitoring and assessment of prosthetic implant failure; and P02M, the first device for monitoring tissue oxygenation at a specific location in real time. P02M is initially being tested for continual monitoring of tissue and vascular viability in the feet of diabetics. Diabetes can cause peripheral artery disease and peripheral neuropathy, putting patients at risk for foot ulcers. BBI is based in Los Angeles and maintains a European office in Manchester, UK. For additional information, visit www.bruinbiometrics.com. Follow BBI on Twitter at https://twitter.com/bruinbiometrics.


News Article | February 21, 2017
Site: www.prweb.com

The Colorado Health Access Fund of The Denver Foundation is now accepting funding proposals from organizations and collaboratives working to increase access to behavioral health care and improve health outcomes for high-need populations across Colorado. Approximately $5 million is available for projects and programs that increase health outcomes across the state, particularly in rural communities. Applications are due Friday, March 10, and grants will be awarded in August 2017. Applicants must register with The Denver Foundation’s online application system by Wednesday, March 1. Complete guidelines are available online. The intent of the Colorado Health Access Fund is to help ensure that health care services are equitably available to all Coloradans with high health needs by distributing funds to organizations that serve people in rural, urban, and suburban areas. The fund will prioritize programs that serve those who are low-income and/or experiencing homelessness; have multiple chronic or acute health conditions; and/or lack health insurance coverage, have inadequate coverage, or have significant barriers to accessing coverage. General operating support is also available. Resources will be directed in four project areas: According to a 2014 analysis of the health care landscape conducted by the Colorado Health Institute and commissioned by The Denver Foundation, 15 of the 21 Colorado Health Statistic Regions included mental/behavioral health as a top local public health priority. Furthermore, mental and behavioral health care was cited as a community priority in every community dialogue conducted by CHI. Discussions with health and community foundations identified access to mental health and substance abuse as the most pressing issues statewide. Thus, the Colorado Health Access Fund is focused on increasing access to behavioral health treatment. In 2015, the Colorado Health Access Fund distributed nearly $2.2 million to 28 grantees across Colorado. A summary of the activities and impact of the first cohort of grantees is available here. Overall, the Colorado Health Access Fund seeks to: For more information and to apply, please visit http://denverfoundation.org/community/page/colorado-health-access-fund. About The Colorado Health Access Fund The Colorado Health Access Fund was created in 2015 with an anonymous $40 million gift as a Field of Interest fund at The Denver Foundation. The intent of the fund is to support programs/activities that generally increase access to health care and strive to improve health outcomes for populations in Colorado with high health care needs. The fund will help to ensure health care services are equitably available to all Coloradans with high health needs by distributing the funds to organizations throughout the state. The Colorado Health Access Fund will distribute approximately $5 million per year through 2022. About The Denver Foundation The Denver Foundation is a community foundation that inspires people and mobilizes resources to improve life in Metro Denver. In 2015, the Foundation and its donors awarded more than $97 million in grants. The Denver Foundation has three roles: stewarding an endowment to meet current and future needs for Metro Denver, working with community leaders to address the core challenges that face the community, and managing more than 1,000 charitable funds on behalf of individuals, families, and businesses. For more information, visit http://www.denverfoundation.org.


News Article | February 15, 2017
Site: www.prweb.com

InDemand Interpreting, a technology-enabled language services performance improvement company and a leading video remote interpreting (VRI) provider within Healthcare, announced a webinar: “Telebehavioral Health and Interpreting Services for Underserved Populations: 21st Century Behavioral Health.” This webinar is hosted in partnership with the Telebehavioral Health Institute, an organization that offers telebehavioral health professional training for clinicians from more than 55 countries. This webinar will address the critical issue of providing Behavioral Health to LEP (limited English proficient) patients and increasing access and availability to achieve better outcomes. New care models and payment structures are evolving to answer provider concerns. In this webinar, participants will gain an understanding of: The featured speaker for this webinar is Marlene M. Maheu, Ph.D., donned the “telepsychology visionary,” and executive director for Telebehavioral Health Institute. Dr. Maheu began delivering telehealth services in 1994 and she is now a consultant, researcher, author, trainer, keynoter and company founder. Casey Zanetti, Vice President of Marketing for InDemand Interpreting, will lead the discussion on understanding LEP populations and their impact on behavioral health, laws that require language access for LEP populations and technologies that can assist with this growing need. InDemand Interpreting connects health care professionals to medically trained and qualified interpreters 24 hours a day, seven days a week, in more than 200 languages, including American Sign Language (ASL). “We are delighted to partner with the Telebehavioral Health Institute to conduct a webinar that will benefit healthcare organizations nationwide,” said Cecil Kost, Chairman and CEO of InDemand Interpreting. “Video remote interpreting offers an accessible, cost effective and reliable language services solution to meet the needs of telebehavioral health for use in all healthcare settings.” For more information about the webinar and to register, visit: https://www.indemandinterpreting.com/upcoming-events/webinar-21st-century-behavioral-health-technology-can-help-increase-access-underserved-populations/ About InDemand Interpreting InDemand Interpreting was founded in 2007 with the vision of ensuring that every patient receives the highest quality healthcare, regardless of language, cultural background or disability. By delivering the most experienced medical interpreters and highest quality video technology InDemand Interpreting provides doctors, nurses and clinicians the language access they need to provide the best possible care. Visit InDemand at http://www.indemandinterpreting.com

Loading Health Institute collaborators
Loading Health Institute collaborators